Cuperus Nienke, van den Hout Wilbert B, Hoogeboom Thomas J, van den Hoogen Frank H J, Vliet Vlieland Thea P M, van den Ende Cornelia H M
Sint Maartenskliniek, Nijmegen, The Netherlands.
Leiden University Medical Center, Leiden, The Netherlands.
Arthritis Care Res (Hoboken). 2016 Apr;68(4):502-10. doi: 10.1002/acr.22709.
To evaluate, from a societal perspective, the cost utility and cost effectiveness of a nonpharmacologic face-to-face treatment program compared with a telephone-based treatment program for patients with generalized osteoarthritis (GOA).
An economic evaluation was carried out alongside a randomized clinical trial involving 147 patients with GOA. Program costs were estimated from time registrations. One-year medical and nonmedical costs were estimated using cost questionnaires. Quality-adjusted life years (QALYs) were estimated using the EuroQol (EQ) classification system, EQ rating scale, and the Short Form 6D (SF-6D). Daily function was measured using the Health Assessment Questionnaire (HAQ) disability index (DI). Cost and QALY/effect differences were analyzed using multilevel regression analysis and cost-effectiveness acceptability curves.
Medical costs of the face-to-face treatment and telephone-based treatment were estimated at €387 and €252, respectively. The difference in total societal costs was nonsignificantly in favor of the face-to-face program (difference €708; 95% confidence interval [95% CI] -€5,058, €3,642). QALYs were similar for both groups according to the EQ, but were significantly in favor of the face-to-face group, according to the SF-6D (difference 0.022 [95% CI 0.000, 0.045]). Daily function was similar according to the HAQ DI. Since both societal costs and QALYs/effects were in favor of the face-to-face program, the economic assessment favored this program, regardless of society's willingness to pay. There was a 65-90% chance that the face-to-face program had better cost utility and a 60-70% chance of being cost effective.
This economic evaluation from a societal perspective showed that a nonpharmacologic, face-to-face treatment program for patients with GOA was likely to be cost effective, relative to a telephone-based program.
从社会角度评估非药物面对面治疗方案与电话治疗方案相比,用于治疗广泛性骨关节炎(GOA)患者的成本效用和成本效益。
在一项涉及147例GOA患者的随机临床试验中同时进行经济评估。根据时间记录估算方案成本。使用成本调查问卷估算一年的医疗和非医疗成本。使用欧洲五维度健康量表(EQ)分类系统、EQ评分量表和简版6D量表(SF - 6D)估算质量调整生命年(QALY)。使用健康评估问卷(HAQ)残疾指数(DI)测量日常功能。使用多水平回归分析和成本效益可接受性曲线分析成本和QALY/效果差异。
面对面治疗和电话治疗的医疗成本分别估计为387欧元和252欧元。社会总成本差异不显著,略有利于面对面治疗方案(差异708欧元;95%置信区间[95%CI] - 5058欧元,3642欧元)。根据EQ,两组的QALY相似,但根据SF - 6D,显著有利于面对面治疗组(差异0.022[95%CI 0.000,0.045])。根据HAQ DI,日常功能相似。由于社会成本和QALY/效果均有利于面对面治疗方案,无论社会支付意愿如何,经济评估都支持该方案。面对面治疗方案具有更好成本效用的可能性为65 - 90%,具有成本效益的可能性为60 - 70%。
从社会角度进行的这项经济评估表明,相对于电话治疗方案,针对GOA患者的非药物面对面治疗方案可能具有成本效益。